Purine Antimetabolites associated Pneumocystis Jiroveci Pneumonia.
Lipin LukosePawar Mansi ShantaramAlan RajGouri NairAina M ShajuSubeesh K ViswamPublished in: Pharmacoepidemiology and drug safety (2023)
A total of 7073 reports associated with pneumocystis jiroveci pneumonia were present in the database, of which 899 reports were associated with purine antimetabolites. A crude signal strength of ROR 15.76(14.70-16.91) was obtained for purine antimetabolites associated PJP, with the highest signal strength reported with fludarabine and thioguanine [ROR 19.63 (17.42-22.13); 19.45(13.21-28.63)]. Stratifying the cases based on autoimmune disorders and the cancer population revealed an ROR of 3.33(2.46-4.50) and 2.93(2.26-3.79) respectively. The highest risk of PJP with use of PAs was observed amongst children with a higher risk of nearly 2 times than the adult population [ROR 11.57(9.16-14.62)] CONCLUSIONS: Our study provided evidence on the occurrence of PJP with the use of purine antimetabolites among the autoimmune and cancer population. We identified signals for PJP with azathioprine, mercaptopurine, thioguanine, cladribine, fludarabine and clofarabine. More research with a superior epidemiological study design of a defined population is required to validate these findings.